Melinta是Cempra制药公司的继承实体。Cempra制药公司位于北卡罗来纳州教堂山市,于2005年11月18日成立,是一家开发抗细菌...查看全文
用户48783635432019-04-10 11:18
【4月9日医药股盘点】$Histogenics(HSGX)$$PhaseBio制药(PHAS)$ $Melinta Therapeutics(MLNT)$ 细胞疗法公司Histogenics同制药公司Ocugen合并,上涨56%;制药公司PhaseBio Pharmaceuticals上涨17.15%;抗生素开发公司Melinta Therapeutics上涨15.15%等。查看全文网页链接查看全文
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-02-04 AccNo: 0001193125-19-026565 Size: 46 KB 网页链接
$Melinta Therapeutics(MLNT)$ 8-K - Current report Filed: 2019-02-04 AccNo: 0001193125-19-026564 Size: 46 KBItem 2.02: Results of Operations and Financial ConditionItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Melinta Therapeutics(MLNT)$ DEFR14A - Revised definitive proxy soliciting materials Filed: 2019-01-29 AccNo: 0001193125-19-019504 Size: 2 MB 网页链接
$Melinta Therapeutics(MLNT)$ DEFR14A - Revised definitive proxy soliciting materials Filed: 2019-01-29 AccNo: 0001193125-19-019504 Size: 2 MB 网页链接
$Melinta Therapeutics(MLNT)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-01-16 AccNo: 0001193805-19-000060 Size: 168 KB 网页链接
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-01-16 AccNo: 0001193125-19-009983 Size: 1 MB 网页链接
$Melinta Therapeutics(MLNT)$ 8-K - Current report Filed: 2019-01-16 AccNo: 0001193125-19-009980 Size: 1 MBItem 1.01: Entry into a Material Definitive AgreementItem 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Reg...
$Melinta Therapeutics(MLNT)$ PRER14A - Preliminary Proxy Soliciting materials Filed: 2019-01-15 AccNo: 0001193125-19-009884 Size: 2 MB 网页链接
$Melinta Therapeutics(MLNT)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-01-03 AccNo: 0001193125-19-001672 Size: 107 KB 网页链接
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-01-03 AccNo: 0001193125-19-000944 Size: 828 KB 网页链接